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Abstract
Background: Thymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in
colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected
CRC who received adjuvant chemotherapy and correlated it with clinical outcome.
Methods:  All patients diagnosed with CRC between 1989 and 2007 and treated with adjuvant
chemotherapy within Hellenic Cooperative Oncology Group's (HeCOG) protocols, were identified.
Archival paraffin-embedded tumor tissues were used for immunohistochemical detection of TS and Topo
I. Immunohistochemistry was performed on tissue microarray slides using monoclonal antibodies against
TS and Topo I. The results were correlated with survival (OS) and disease free survival (DFS).
Results: A cohort of 498 patients with a median age of 61 years and Dukes' stage B (49%) and C (51%)
fulfilled the criteria of the study. All patients received adjuvant 5-FU-based chemotherapy, 38% irinotecan-
containing. Positive TS and Topo I expression was found in 43% and 48% of cases, respectively. Five-year
OS was 74% and DFS was 68%. In univariate analysis no association of TS and Topo I expression with OS
and DFS was identified. In multivariate analysis however, Topo I expression was associated with a reduced
risk of death (HR = 0.61, 95% CI 0.42-0.88, p = 0.009). In the irinotecan-treated subgroup, those patients
who expressed Topo I had a better OS (HR = 0.47, 95% CI 0.23-0.94, p = 0.033).
Conclusion: Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing
adjuvant chemotherapy. However randomised prospective trials are needed to confirm these results.
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Background
Colorectal cancer is the second most common cause of
death from cancer in the western world[1]. Postoperative
adjuvant chemotherapy has clearly been shown to
improve survival in stage III colon cancer and is now
widely accepted as standard therapy[2]. However, the
need for adjuvant chemotherapy in stage II disease hasn't
been determined as yet, with the exception of patients
who are considered to be at high risk for recurrence[2].
Therefore, biological markers that could reliably predict
survival are needed.
The antimetabolite, 5-Fluorouracil (5-FU), remains the
mainstay of chemotherapy for colorectal cancer (CRC).
Adjuvant treatment with 5-FU has been shown to improve
survival in stage III colon carcinoma patients by 10%-
15%[3]. Survival has further been improved with the
addition of the newer drugs oxaliplatin and irinotecan[4].
Although increasing evidence indicates that stage II CRC
patients could also have a benefit from 5-FU-based thera-
pies, only a relatively small proportion of patients appear
to benefit from this treatment[5]. Therefore, considerable
effort has been directed towards the identification of
biomarkers that can accurately predict tumor response.
These have included intratumoral levels of thymidylate
synthase (TS), TP53 mutations, microsatellite instability,
and chromosomal deletions [6-8].
Thymidylate synthase is essential for de novo DNA syn-
thesis, by catalyzing the conversion of deoxy-uridine
monophosphate (dUMP) to deoxy-thymidine mono-
phosphate (dTMP). The TS protein is the target for the
antitumor effect of fluoropyrimidines. Inhibition of TS by
the 5-FU metabolite fluorodeoxyuridine monophosphate
has been identified as the main mechanism of 5-FU
action[9]. A number of studies have investigated the rela-
tionship between TS protein expression and survival in
CRC patients. Although most have reported poor overall
survival (OS) and progression-free survival (PFS) with
tumors expressing high TS levels, the prognostic value of
TS expression between studies has not been estab-
lished[10].
Topoisomerase I (Topo I) is an essential enzyme with piv-
otal role in regulating DNA topology[11]. Topo I targeting
antineoplastic drugs, such as camptothecins or etopo-
sides, form stable Topo I-DNA cleavage complexes and
inhibit Topo I activity by impeding DNA religation[12].
Topo I is expressed in primary colorectal carcinomas and
metastases, but its predictive role in patients undergoing
anti-Topo I treatment has not been defined as yet[13,14].
In our study we looked in retrospect, whether the immu-
nohistochemical expression of TS and Topo I (which is
the target of irinotecan) had any predictive significance in
a large cohort of patients with colorectal cancer, who
received several schedules of 5-FU-based adjuvant chemo-
therapy.
Methods
From the Hellenic Cooperative Oncology Group's
(HeCOG) electronic database, all patients with Dukes'
stage C and high risk B CRC who received post-operative
adjuvant chemotherapy within several treatment proto-
cols between 1989 and 2007 were identified. All patients
had participated in the five 5-FU-based adjuvant therapy
trials conducted by HeCOG, the results of which have
already been published [15-19]. In the first trial, from
August 1989 to July 1997, eligible patients with CRC were
randomized to receive adjuvant 5-FU/Leucovorin (LV)
with or without Interferon alpha (IFNa). In the second
trial, from October 1989 to February 1997, patients with
rectal cancer were randomized to receive postoperative
concomitant radiotherapy and bolus 5-FU chemotherapy
with or without additional chemotherapy with 5-FU and
high dose LV. In the third randomized trial, in which
enrollment took place between October 1999 and
December 2007, patients with rectal cancer received radi-
otherapy and adjuvant 5-FU/LV chemotherapy with or
without the addition of irinotecan (CPT-11). Our search
also identified a fourth small feasibility study conducted
prior to the last one, with irinotecan and 5-FU/LV adju-
vant chemotherapy given to patients with rectal cancer. In
addition, in a fifth randomized trial published in an
abstract form, in which enrollment took place between
January 1999 and September 2004, patients with colon
cancer received adjuvant 5-FU/Folinic acid chemotherapy
with or without the addition of irinotecan. These patients
were also included in the total study population. Only
patients that received adjuvant chemotherapy were
retrieved and selected for the present study. Despite the
differences in treatment modalities, the individual trials
described above were very similar with regard to the eligi-
bility criteria and evaluation standards employed.
Paraffin-embedded tumor tissue was available from a
non-random subset of study participants. Only patients
with tumor tissue available in the HeCOG tumor tissue
bank were included in the present study. Signed informed
consent was obtained for the treatment. Clinical protocols
were approved by the institutional review boards of each
participating centre. A waiver of consent for the use of
archival tissue was provided by the Bioethics Committee
of the Aristotle University of Thessaloniki. All patients
were censored 5 years after randomization for disease-free
survival. Patients were followed for a minimum of 3 years
after study randomization.
Tissue samples
Archival formalin-fixed paraffin-embedded tissue sam-
ples were collected from nine different hospitals between
1989 and 2007. Fixation, tissue processing, and storageBMC Cancer 2009, 9:339 http://www.biomedcentral.com/1471-2407/9/339
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protocols of these tissue samples were identified and
appeared to be highly variable. The H&E sections were
reviewed by a pathologist (MB) for the evaluation of tis-
sue adequacy, confirmation of the diagnosis and calcula-
tion of the tumor percentage in each case.
Tissue Microarray (TMA) construction
Twenty-one TMA blocks, containing from 91 to 343 tissue
cores, were constructed (by MB) with a manual microar-
rayer (Beecher Instruments, Sun Prairie, WI, USA) to
include 7 cores (0.6 mm diameter) from each CRC case,
randomly obtained from both the central part and the
invasive front of the tumor. In each TMA block, 7 cores in
total, from thyroid, skin and tonsil tissue were included as
controls of immunostaining, block orientation and align-
ment.
Immunohistochemistry (IHC)
The mouse monoclonal anti-human Thymidylate Syn-
thase antibody (clone TS 106, Neomarkers, Fremont, CA,
USA) and the mouse monoclonal anti-human Topoi-
somerase I antibody (clone 1D6, Newcastle, UK) were
used for the IHC assays. Antigen unmasking was per-
formed by heating the slides on a hot plate for 20 minutes
with a sodium citrate solution, pH 6.0. After three 5 min
washings with TBS the slides were incubated for 1 hour for
TS and 10 minutes for Topo I with protein block (Power
Block™, BioGenex, San Ramon, CA, USA). The slides were
then incubated overnight at 4°C with TS mAb (dilution
1:300), and for 1 hour at ambient temperature with
Topoisomerase I mAb (dilution 1:100). After washing of
the primary antibody, the slides were incubated in a
biotin-free detection system (HRP super sensitive non-
biotin detection system, BioGenex) for a total of 40 min-
utes. The antigen/antibody complex was visualized using
diaminobenzidine (BioGenex) as a chromogen. Slides
were counterstained with Mayer's hematoxylin. The thy-
roid and skin tissue cores served as negative IHC controls
for the TS and Topo I, while the tonsil tissue as a positive
control for Topo I. A known positive colorectal carcinoma
case and an ovarian carcinoma case were used as external
positive IHC controls for TS and Topo I, respectively.
Evaluation system
The evaluation of all IHC sections was done simultane-
ously by two observers, (I.K. and M.B.) according to pre-
viously proposed/established criteria with slight
modifications [13,20]. Each slide was assigned a score for
intensity and staining pattern using a 4-tier system. Inten-
sity score ranged from 0 to 3 (0 = no staining, 1 = weakly
positive, 2 = moderately positive, and 3 = strongly positive
staining). The staining pattern score, based on the per-
centage of positive tumor cells, ranged from 0-3 (0 = 0 to
5%, 1 = 6 to 25%, 2 = 26% to 50%, 3 = 51% to 100%).
The localization of staining for each protein, cytoplasmic
and/or nuclear for TS, and nuclear or nuclear/cytoplasmic
or solely cytoplasmic for Topo I was also indicated.
Statistical analysis
In order to define TS and Topo I expression status, the
total score was calculated as the sum of the intensity score
and the staining pattern score in each case. Cases with a
total score of at least 4, were considered as TS or Topo I
positive (high expression tumors), whereas cases with a
total score of 0--3 were grouped together and considered
as negative or low expression tumors.
Comparisons between subgroups were performed using
the χ2 test for categorical characteristics and the Mann-
Whitney test for continuous variables. Overall Survival
(OS) was calculated as the time from adjuvant chemother-
apy initiation to the date of death or the date of last con-
tact. Disease Free Survival (DFS) was calculated as the
time from adjuvant chemotherapy initiation to the date of
verified disease progression, the date of death or the date
of last contact. Deaths without prior verification of disease
progression were considered as events in the estimation of
DFS. OS and DFS distributions were estimated by the Kap-
lan-Meier method and comparisons between subgroups
were performed using the log-rank test. In order to esti-
mate the hazard ratios of TS or Topo I status for OS and
DFS, univariate Cox regression analyses were performed
both unadjusted and adjusted for irinotecan chemother-
apy.
In the assessment of the predictive value of TS and Topo I,
the interaction of each of the biomarkers under study with
the irinotecan adjuvant treatment was taken into account.
Multivariate Cox models were also fitted, including
patient's age, sex (female/male), stage (Dukes' B/C), dif-
ferentiation grade (well or moderately differentiated/
poorly differentiated or undifferentiated), Irinotecan con-
taining adjuvant chemotherapy (No/Yes), Topo I expres-
sion (negative/positive), and TS expression (negative/
positive). Variables selection was performed using the
backwards selection procedure based on the likelihood
ratio test. For all comparisons the level of significance was
set at a = 0.05.
Results
Characteristics of the patients and TS and Topo I status
From a total of 1730 CRC patients registered in our data-
base, 498 cases (229 females and 269 males) were eligible
for analysis (Table 1). Median age at diagnosis was 61 years
(range 21-79 years). Most patients had rectal (32%) and
sigmoid (27%) primaries, predominantly moderately dif-
ferentiated (72%). Dukes' stage B and C were equally repre-
sented. All patients were treated within the previously
mentioned therapeutic protocols of HeCOG. In total, 5-
FU/LV chemotherapy was given to 286 patients (248 with-BMC Cancer 2009, 9:339 http://www.biomedcentral.com/1471-2407/9/339
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out IFNa and 38 patients with IFNa), whereas 190 patients
were treated with irinotecan/5-FU/LV. A small number of
patients (3%) were treated with oxaliplatin/5-FU/LV.
Approximately 30% of the patients were treated with radi-
otherapy in the adjuvant setting. The vast majority of these
patients (87%) had rectal cancer (Table 1).
The patients included in the analysis had a significantly
higher percentage of Dukes' stage B2 at diagnosis (49% vs.
43%,  χ2  test, p = 0.034) than the protocol patients
excluded due to inability to obtain tissue for IHC evalua-
tion. The rest of the patient characteristics presented in
Table 1 (age, sex, primary site, and differentiation grade)
were not significantly different.
High TS expression (Figure 1) was found in 212 (43%) of
the cases, whereas in 2% of the patients, expression status
could not be assessed due to inadequate material (Table
2). High expression of Topo I (Figure 2) was found in 238
(48%) of cases. In 3% of the patients the staining for Topo
I was inappropriate for assessing protein status (Table 2).
Relation between TS and Topo I status and survival
With a median follow-up of 63.5 months, 160 relapses
and 126 deaths were recorded. The 3-year OS rate was
84%, the 5-year OS rate 74% and the median survival was
145.7 months. The 3-year DFS rate was 76% and 5-year
DFS rate 68%. In univariate analysis, a non-significant
trend for a poor survival in TS positive patients was
noticed (5-year OS rate 68% vs 77%, median survival 146
months vs 148 months, log-rank p = 0.100). A similar
trend was noticed for DFS (5-year DFS rate 62% vs 72%,
median DFS 123 months vs not reached yet, log-rank p =
0.079) (Figure 3). With regards to Topo I expression, there
was a trend for better survival in patients who expressed
Topo I (5-year OS rate 79% vs 70%, median survival 146
months vs 137 months, p = 0.079). For DFS no such trend
was detected (5-year DFS rate 70% vs 66%, median sur-
vival not reached yet, log-rank p = 0.691) (Figure 4).
In multivariate analysis (Table 3), positive Topo I expres-
sion was found to be significantly associated with
improved overall survival (HR = 0.61, 95% CI 0.42-0.88,
wald p = 0.009), but no such association was seen with
DFS (HR = 0.80, 95% CI 0.58-1.11, wald p = 0.18). TS
Table 1: Patient demographics.
All patients N = 498
Age 
Median (range) 63 (21-79)
N (%)
Sex
Female 229 (46)
Male 269 (54)
Primary site
Rectum 161 (32)
Sigmoid 137 (27)
Cecum 69 (14)
Ascending 57 (11)
Descending 37 (7)
Transverse 35 (7)
Unknown 2 (0.4)
Stage at diagnosis
Dukes' B 246 (49)
Dukes' C 252 (51)
Differentiation Grade
Good 67 (14)
Moderate 357 (72)
Poor 62 (12)
Undifferentiated 3 (1)
Unknown 9 (2)
Adjuvant radiotherapy
No 325 (65)
Yes 143 (29)
Unknown 30 (6)
Adjuvant chemotherapy
5FU/LV/Irinotecan 190 (38)
5FU/LV ± IFNα 286 (57)
5FU/LV/Oxaliplatin 17 (3)
Other 5 (1)
Immunohistochemical detection of TS in TMA cores of colorectal carcinoma cases Figure 1
Immunohistochemical detection of TS in TMA cores of colorectal carcinoma cases. Strong cytoplasmic staining, 
graded as positive with a total score of 6/6 (a); mild focal cytoplasmic staining, graded as negative with a total score of 2/6 (b); 
absence of staining in a signet-ring cell carcinoma, with a total score of 0/6 (c). (Magnification: ×100).
abcBMC Cancer 2009, 9:339 http://www.biomedcentral.com/1471-2407/9/339
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expression was not found to be an independent prognos-
tic factor for OS or DFS.
Interaction between Topo I and TS adjusted for all factors
included in the multivariate analysis was not significant
either for OS or DFS (wald, p = 0.632 and p = 0.798
respectively). However, if looking at each of the four
groups seperately, (TS/Topo I both positive vs TS negative/
Topo I positive vs TS positive/Topo I negative vs TS/Topo
I both negative), the TS positive/Topo I negative group
was associated with shorter OS compared to the other
three groups (wald p = 0.036). Adjusting for all other fac-
tors (stage, grade and irinotecan treatment) this result
remains significant (wald p = 0.022).
Relation between TS and Topo I status and benefit from 
adjuvant irinotecan containing chemotherapy
In total, 190 patients were treated with irinotecan and 5-
FU/LV chemotherapy. There were no differences in sur-
vival between patients who received irinotecan and those
who did not. However median OS and DFS have not been
reached yet. Interaction of irinotecan containing adjuvant
chemotherapy with the two biomarkers assessed was not
shown to be significant. Nevertheless, in the absence of
irinotecan treatment, positive TS expression tends to have
a negative effect on survival (HR = 1.50, 95% CI 0.98-
2.30, wald p = 0.068). This effect is not seen in CPT-11
treated patients (HR = 1.06, 95% CI 0.56-2.00, wald p =
0.857). Results for DFS were similar. In the subgroup of
irinotecan treated patients the effect of TS expression was
not statistically significant (HR = 1.02, 95% CI 0.59-1.77,
wald p = 0.946), while in the absence of irinotecan, TS was
associated with a worse DFS (HR = 1.50, 95% CI 1.03-
2.19, wald p = 0.036) (Figure 5).
On the other hand, positive Topo I expression seems to
have a prophylactic effect in terms of OS in irinotecan
treated patients by reducing the hazard for death by 53%
(HR = 0.47, 95% CI 0.23-0.94, wald p = 0.033). In the
absence of irinotecan, Topo I expression has no effect on
OS (HR = 0.86, 95% CI 0.55-1.32, wald p = 0.481). Effect
of Topo I expression on DFS was not shown to be statisti-
cally significant in either irinotecan treated or non-treated
patients (HR = 0.76, 95% CI 0.43-1.34, wald p = 0.338
and HR = 1.02, 95% CI 0.69-1.50, wald p = 0.925, respec-
tively) (Figure 6).
Immunohistochemical detection of Topo I in TMA cores of colorectal carcinoma cases Figure 2
Immunohistochemical detection of Topo I in TMA cores of colorectal carcinoma cases. Strong nuclear staining, 
graded as positive with a total score of 6/6 (a); moderate, diffused, predominantly cytoplasmic staining, graded as positive with 
a total score of 5/6 (b); mild focal nuclear and cytoplasmic staining, graded as low expression/negative with a total score of 2/6 
(c). (Magnification: ×100).
a bc
Table 2: Immunohistochemical expression of thymidylate 
synthase (TS) and topoisomerase I (Topo I) in tumor tissue 
samples (N = 498).
TS score N %
01 5 7 3 2
1 1 0.2 Negative/Low
2 47 9 expression
37 3 1 5
41 0 5 2 1
5 60 12 Positive/High
6 47 9 expression
Non Evaluable 8 2
Topo I score
01 7 0 3 4
2 19 4 Negative/Low
3 54 11 expression
41 2 6 2 5
5 80 16 Positive/High
6 32 6 expression
Non Evaluable 17 3BMC Cancer 2009, 9:339 http://www.biomedcentral.com/1471-2407/9/339
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Discussion
In our study we failed to demonstrate an association
between TS and clinical outcome in patients with resected
CRC treated with adjuvant chemotherapy. However, a
non-significant trend for poor OS and DFS was seen in TS
positive patients. High TS expression levels have generally
been associated with poor overall survival in CRC. Most of
the studies to date show that high levels of TS correlate
with lower response rates in patients with advanced dis-
ease treated with fluoropyrimidine-based therapies [21-
23].
In the adjuvant setting, a meta-analysis, which included
2610 patients with resected CRC, found a hazard ratio of
recurrence of 1.35 for high TS, although the adjuvant
treatment status of patients in many of the studies was not
well defined[24]. Only few trials had a sufficiently large
sample to explore the efficacy of fluorouracil-based adju-
vant chemotherapy according to TS expression. Allegra et
al. failed to demonstrate a consistent and significant asso-
ciation between TS and either OS or DFS in 465 patients
with Dukes B and C disease[20]. Moreover, Popat et al., in
a large prospective trial of the prognostic value of the
molecular markers TS and p53 in resected CRC, similarly
failed to demonstrate such an association of TS expression
and clinical outcome in the adjuvant setting[25].
In controversy, Kornmann et al. showed, in a cohort of
309 patients with resected CRC treated with adjuvant 5-
FU therapy, that those with high TS survived longer than
those with low TS[26]. Recently, Jansen et al. found that
high TS gene copy numbers were associated with a signif-
icantly higher risk of recurrence and death in patients with
colorectal cancer treated with adjuvant 5-FU chemother-
apy[27]. It appears therefore, that the prognostic role of TS
expression in CRC remains controversial in the adjuvant
setting. Several hypotheses have been suggested to explain
this occurrence, including differences in TS levels in pri-
mary tumors and locoregional lymph node metastases,
modulation of 5-FU resistance by other molecules such as
p53 and DPD, differences in 5-FU scheduling, as well as
methodological problems and biases in the assessment of
TS in individual studies[10,25]. In addition, no relation-
ship between TS protein expression and TS enzyme activ-
ity, measured by FdUMP-binding or TS catalytic assays,
was found in CRC patients[28], which may be another
factor contributing to the conflicting data.
Our finding of a significant association of high TS expres-
sion with shorter DFS in a subgroup of patients not
treated with irinotecan adds to the controversy. One pos-
sible explanation is that the predictive value of TS can
only be detected in the non-irinotecan treated group,
OS (a) and DFS (b) in TS positive (red line) and TS negative (blue line) patients (log-rank p = 0.100 and p = 0.079, respectively) Figure 3
OS (a) and DFS (b) in TS positive (red line) and TS negative (blue line) patients (log-rank p = 0.100 and p = 
0.079, respectively).
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since there is no data available connecting TS expression
with responsiveness to irinotecan. However the possibil-
ity that this is a result of the increased heterogeneity, with
regards to the administered chemotherapy regimens in
this group, cannot be excluded.
While there are data regarding the prognostic role of TS in
the adjuvant setting in patients with CRC, little is known
about the possible role of Topo I. Topo I is the target of the
active irinotecan metabolite SN 38 and may therefore be
a plausible predictive marker for irinotecan containing
chemotherapy[14]. Expression of Topo I varies between
43% and 51% in published series, while Topo I enzymatic
activity has been found highly variable between malig-
nant and normal tissue of patients with CRC[13,29,30].
In our study, in a multivariate analysis, it turned out that
Topo I expression was an independent prognostic factor
for survival by reducing the hazard ratio of death by 39%.
OS (a) and DFS (b) in Topo I positive (red line) and Topo I negative (blue line) patients (log-rank p = 0.079 and p = 0.691,  respectively) Figure 4
OS (a) and DFS (b) in Topo I positive (red line) and Topo I negative (blue line) patients (log-rank p = 0.079 and 
p = 0.691, respectively).
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Table 3: Multivariate Cox regression analysis.
OS DFS
HR 95% CI p HR 95% CI p
Stage
Dukes B 1 - 1 -
Dukes C 2.75 1.84-4.12 <0.001 2.46 1.74-3.48 <0.001
Differentiation grade
W e l l  o r  M o d e r a t e 1- 1-
Poor 2.51 1.60-3.94 <0.001 2.56 1.73-3.79 <0.001
TS expression
Negative/Low expression 1 - 1 -
Positive/High 1.37 0.94-1.97 0.098 1.32 0.95-1.82 0.097
Topo I expression
Negative/Low expression 1 - 1 -
Positive/High 0.61 0.42-0.88 0.009 0.80 0.58-1.11 0.180
CPT-11 treatment
N o 1- 1-
Yes 0.78 0.52-1.16 0.216 0.79 0.56-1.12 0.187BMC Cancer 2009, 9:339 http://www.biomedcentral.com/1471-2407/9/339
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In a subgroup analysis, it seemed that this survival benefit
applies only to patients who expressed Topo I and were
treated with adjuvant irinotecan containing chemother-
apy.
Nevertheless, we were not able to show statistical benefit
in DFS from the addition of irinotecan. We postulate that
possible explanations might be the relatively small
number of patients that received adjuvant irinotecan
chemotherapy, the retrospective nature of our study and
the heterogeneity of the patient population. Several phase
III randomized trials did not show any incremental bene-
fit from the addition of irinotecan to 5-FU/LV adjuvant
chemotherapy in patients with colorectal cancer[18,31].
Whether Topo I expression is a favorable prognostic
marker by itself and whether this can further be improved
by adding irinotecan in the adjuvant treatment of this
population still remains unanswered.
Very recently, Braun and colleagues investigated a panel of
possible biomarkers for chemotherapy efficacy in a large
cohort of patients with metastatic colorectal cancer,
receiving chemotherapy within the FOCUS trial[32].
Between several molecules tested, they found that high
levels of Topo I (assessed by similar to our study IHC
methods) were associated with a major survival benefit
from first line chemotherapy regimens containing either
irinotecan or oxaliplatin, corresponding to a median sur-
vival advantage of 5.3 months. Nevertheless, there is still
lack of information regarding the prognostic role of Topo
I in the adjuvant setting.
Conclusion
Our results failed to demonstrate an association between
TS and clinical outcome in patients with CRC treated with
various regimens of 5-FU based adjuvant chemotherapy.
On the other hand we have shown that Topo I is an inde-
OS (a) and DFS (b) in TS positive (red line) and TS negative (blue line) CPT-11 treated patients (log-rank p = 0.868 and p =  0.937, respectively) Figure 5
OS (a) and DFS (b) in TS positive (red line) and TS negative (blue line) CPT-11 treated patients (log-rank p = 
0.868 and p = 0.937, respectively). OS (c) and DFS (d) in TS positive (red line) and TS negative (blue line) non-CPT-11 
treated patients (log-rank p = 0.062 and p = 0.035, respectively).
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pendent prognostic factor of survival. Adjuvant irinotecan
containing chemotherapy might confer a survival advan-
tage in CRC patients expressing Topo I, but this is still an
open issue amenable to further investigation.
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